LIMITED OFFER
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code needed.
Side Effects of Drugs Annual
A worldwide yearly survey of new data in adverse drug reactions
- 1st Edition, Volume 34 - December 14, 2012
- Editor: Jeffrey K Aronson
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 4 - 5 9 4 9 9 - 0
- eBook ISBN:9 7 8 - 0 - 4 4 4 - 5 9 5 0 3 - 4
The Side Effects of Drugs Annual was first published in 1977. It has been continually published since then as a yearly update to the voluminous encyclopedia, Meyler's Side Effects… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteThe Side Effects of Drugs Annual was first published in 1977. It has been continually published since then as a yearly update to the voluminous encyclopedia, Meyler's Side Effects of Drugs. Each new Annual continues to provide clinicians and medical investigators with a reliable and critical yearly survey of new data and trends in the area of adverse drug reactions and interactions. An international team of specialists has contributed to the informative Annual by critically interpreting it and by pointing to whatever is misleading.
- Provides a critical yearly survey of new data and trends
- Special reviews in this Annual include, among other topics, epidemiology of the use of ecstasy, paracetamol and the risk of asthma, combination vaccines/multiple immunizations, interactions of herbal medicines with warfarin, and tyrosine kinase inhibitors
Pharmacologists, clinicians, pharmaceutical companies, clinical toxicologists, clinical pharmacologists and medical libraries
Series Page
Contributors
Special reviews
Cumulative indexes of special reviews, Annuals 11–33
1. Index of drugs
2. Index of adverse reactions
Table of Essays, Annuals 1–33
Mechanistic and clinical descriptions of adverse drug reactions
1 EIDOS
2 DoTS
Definitive (between-the-eyes) adverse drug reactions
How to use this book
The scope of the Side Effects of Drugs Annuals
Period covered
Selection of material
Classification of drugs
Names of drugs and chemicals
System of tagging references
Indexes
Abbreviations
Side effects of drugs essay
An agenda for research into adverse drug reactions
Systematic reviews
Teleoanalysis
Conclusions
1. Central nervous system stimulants and drugs that suppress appetite
Amphetamines [SED-15, 180; SEDA-31, 1; SEDA-32, 1; SEDA-33, 1]
Methylxanthines
Drugs that suppress appetite [SEDA-30, 7; SEDA-31, 9; SEDA-32, 16; SEDA-33, 13]
Drugs used in Alzheimer’s disease [SEDA-31, 10; SEDA-32, 19; SEDA-33, 15]
References
2. Antidepressant drugs
General
Selective serotonin re-uptake inhibitors (SSRIs) [SED-15, 3109; SEDA-31, 18; SEDA-32, 33; SEDA-33, 26]
Serotonin and noradrenaline re-uptake inhibitors (SNRIs)
Tricyclic antidepressants
Other antidepressants
References
3. Lithium
References
4. Drugs of abuse
Cannabinoids [SED-15, 614; SEDA-31, 33; SEDA-32, 55; SEDA-33, 55]
Opioid analgesics
References
5. Hypnosedatives and anxiolytics
Azaspirones [SEDA-32, 75; SEDA-33, 71]
Benzodiazepines [SED-15, 429; SEDA-31, 57; SEDA-32, 75; SEDA-33, 71]
Benzodiazepine-like drugs
Benzodiazepine antagonists
Other hypnosedatives
References
6. Antipsychotic drugs
General [SED-15, 2438; SEDA-32, 83; SEDA-33, 89]
Individual drugs
References
7. Antiepileptic drugs
General
References
8. Opioid analgesics and narcotic antagonists
General
Opioid receptor agonists
Partial opioid receptor agonists
Opioid receptor antagonists
References
9. Anti-inflammatory and antipyretic analgesics and drugs used in gout
Amidopyrine and related compounds
Aniline derivatives [SED-15, 2679; SEDA-33, 244]
Anthranilic acid derivatives
Arylalkanoic acid derivatives [SED-15, 2555; SEDA-31, 186; SEDA-32, 229; SEDA-33, 245]
COX-2-selective inhibitors [SEDA-31, 190; SEDA-32, 232; SEDA-33, 246]
Indoleacetic acids [SEDA-33, 247]
Oxicams [SED-15, 2555; SEDA-32, 233; SEDA-33, 247]
Salicylates [SED-15, 15; SEDA-30, 128; SEDA-33, 248]
Miscellaneous drugs
Drugs used in the treatment of gout
References
10. General anesthetics and therapeutic gases
Anesthetic vapors [SEDA-31, 217; SEDA-32, 243; SEDA-33, 257]
Other vapors
Intravenous agents: Non-barbiturate anesthetics
Intravenous agents: Barbiturate anesthetics
References
11. Local anesthetics
General
Effects related to modes of use [SED-15, 2121; SEDA-31, 233; SEDA-32, 262; SEDA-33, 281]
Caudal, epidural, and spinal anesthesia
Tumescent anesthesia
Individual compounds
References
12. Neuromuscular blocking agents and skeletal muscle relaxants
Depolarizing neuromuscular blocking agents
Non-depolarizing neuromuscular blocking agents [SED-15, 2489; SEDA-31, 248; SEDA-32, 274; SEDA-33, 301]
Skeletal muscle relaxants
References
13. Drugs that affect autonomic functions or the extrapyramidal system
Drugs that stimulate both alpha- and beta-adrenoceptors [SEDA-31, 259; SEDA-32, 281; SEDA-33, 313]
Drugs that predominantly stimulate alpha1-adrenoceptors [SEDA-31, 264; SEDA-32, 283; SEDA-33, 318]
Drugs that stimulate beta1-adrenoceptors [SEDA-31, 265; SEDA-32, 284; SEDA-33, 265]
Drugs that stimulate beta2-adrenoceptors
Drugs that stimulate dopamine receptors [SEDA-31, 2039; SEDA-33, 266]
Other drugs that increase dopamine activity
Drugs that affect the cholinergic system [SEDA-31, 272; SEDA-32, 290; SEDA-33, 324]
References
14. Dermatological drugs, topical agents, and cosmetics
Cosmetics
Dermal fillers
Dyestuffs [SEDA-15, 1573; SEDA-31, 288; SEDA-32, 296]
Hair straighteners [SEDA-32, 296]
Fragrances
Glucocorticoids, topical
Phototherapy and photochemotherapy [SED-15, 2823; SEDA-32, 297]
Sunscreens
Vitamin A (retinoids) [SED-15, 3653; SEDA-32, 298; for vitamin A carotenoids seeChapter 34]
Vitamin D analogues, topical [SED-15, 594; SEDA-31, 293; SEDA-32, 301; for oral vitamin D analogues seeChapter 34]
References
15. Antihistamines (H1 receptor antagonists)
References
16. Drugs that act on the respiratory tract
Inhaled glucocorticoids [SEDA-31, 305; SEDA-32, 311; SEDA-33, 353]
Nasal glucocorticoids
Beta2-adrenoceptor agonists [SEDA-31, 308; SEDA-32, 314; SEDA-33, 357]
Anticholinergic drugs [SEDA-31, 311; SEDA-32, 318; SEDA-33, 363]
Leukotriene modifiers [SEDA-31, 312; SEDA-32, 319; SEDA-33, 366]
Phosphodiesterase type IV inhibitors [SEDA-31, 313; SEDA-32, 321; SEDA-33, 367]
References
17. Positive inotropic drugs and drugs used in dysrhythmias
Cardiac glycosides [SED-15, 648; SEDA-31, 321; SEDA-32, 333; SEDA-33, 377]
Herbal glycosides
Other positive inotropic drugs [SED-15, 2822; SEDA-31, 323; SEDA-32, 336; SEDA-33, 378]
Antidysrhythmic drugs
Adenosine receptor agonists [SEDA-31, 324; SEDA-32, 337; SEDA-33, 379]
References
18. Beta-adrenoceptor antagonists and antianginal drugs
Beta-adrenoceptor antagonists [SED-15, 452; SEDA-31, 339; SEDA-32, 363; SEDA-33, 397]
Potassium channel activators
Nitrates, organic [SED-15, 2529; SEDA-32, 366; SEDA-33, 400]
Calcium channel blockers [SED-15, 598; SEDA-31, 340; SEDA-32, 366; SEDA-33, 401]
References
19. Drugs acting on the cerebral and peripheral circulations
Drugs used in the treatment of arterial disorders of the brain and limbs
Drugs used in the treatment of venous disorders
Drugs used in the treatment of migraine
Other peripheral vasodilators
References
20. Antihypertensive drugs
General
Angiotensin-converting enzyme inhibitors [SED-15, 226; SEDA-31, 350; SEDA-32, 379; SEDA-33, 416]
Angiotensin II receptor antagonists [SED-15, 223; SEDA-31, 358; SEDA-32, 387; SEDA-33, 418]
Dual angiotensin II receptor antagonists/neprilysin antagonists
Direct renin inhibitors [SEDA-31, 360; SEDA-32, 388; SEDA-33, 420]
Endothelin receptor antagonists [SED-15, 1215; SEDA-31, 360; SEDA-32, 389; SEDA-33, 421]
Drugs that act on the sympathetic nervous system [SEDA-31, 362; SEDA-32, 391; SEDA-33, 424]
Postsynaptic α-adrenoceptor antagonists [SEDA-31, 363; SEDA-32, 391; SEDA-33, 425]
Direct vasodilators
References
21. Diuretics
Carbonic anhydrase inhibitors [SED-15, 643; SEDA-31, 371; SEDA-32, 403; SEDA-33, 437]
Thiazide and thiazide-like diuretics [SED-15, 3375; SEDA-31, 372; SEDA-32, 405; SEDA-33, 438]
Loop diuretics [SED-15, 567, 1454; SEDA-31, 375; SEDA-32, 408; SEDA-33, 440]
Aldosterone receptor antagonists
Spironolactone [SED-15, 3176; SEDA-31, 375; SEDA-32, 409; SEDA-33, 440]
Osmotic diuretics
References
22. Metals
References
23. Metal antagonists
Iron chelators
Penicillamine and related drugs [SED-15, 2729; SEDA-31, 403; SEDA-32, 430; SEDA-33, 472]
Other chelators
Polystyrene sulfonates [SED-15, 2894; SEDA-32, 433; SEDA-33, 474]
References
24. Antiseptic drugs and disinfectants
Aldehydes [SED-15, 1439, 1513; SEDA-31, 409; SEDA-32, 437; SEDA-33, 479]
Bisbiguanides
Cationic surfactants
Halogens
Iodophors [SED-15, 1896; SEDA-31, 411; SEDA-32, 440; SEDA-33, 485]
Phenolic compounds [SED-15, 2800; SEDA-32, 441; SEDA-33, 485]
References
25. Penicillins, cephalosporins, other beta-lactam antibiotics, and tetracyclines
Beta-lactam antibiotics [SED-15, 478; SEDA-31, 420; SEDA-32, 447; SEDA-33, 491]
Carbapenems [SED-15, 638; SEDA-31, 420; SEDA-32, 448; SEDA-33, 491]
Cephalosporins [SED-15, 688; SEDA-31, 422; SEDA-32, 448; SEDA-33, 493]
Monobactams and monocarbams [SED-15, 2378; SEDA-31, 423; SEDA-32, 450; SEDA-33, 494]
Penicillins [SED-15, 2756; SEDA-31, 424; SEDA-32, 450; SEDA-33, 495]
Tetracyclines and glycylcyclines [SED-15, 3330; SEDA-31, 419; SEDA-32, 451; SEDA-33, 497]
References
26. Miscellaneous antibacterial drugs
Aminoglycosides [SED-15, 118; SEDA-31, 427; SEDA-32, 461; SEDA-33, 509]
Fluoroquinolones [SED-15, 1396; SEDA-31, 429; SEDA-32, 464; SEDA-33, 514]
Glycopeptides [SEDA-31, 435; SEDA-32, 469; SEDA-33, 519]
Ketolides [SED-15, 1976; SEDA-31, 436; SEDA-32, 471; SEDA-33, 521]
Lincosamides [SED-15, 2063; SEDA-31, 437; SEDA-32, 472; SEDA-33, 522]
Macrolides [SED-15, 2183; SEDA-31, 437; SEDA-32, 472; SEDA-33, 522]
Nitrofurantoin [SED-15, 2542; SEDA-31, 439; SEDA-32, 476; SEDA-33, 525]
Oxazolidinones [SED-15, 2645; SEDA-31, 439; SEDA-32, 474; SEDA-33, 525]
Polymyxins [SED-15, 2891; SEDA-31, 441; SEDA-32, 476; SEDA-33, 527]
Streptogramins [SED-15, 3182; SEDA-31, 442; SEDA-32, 528]
Sulfonamides, trimethoprim, and co-trimoxazole [SED-15, 3216, 3510; SEDA-31, 442; SEDA-32, 477; SEDA-33, 528]
Other antimicrobial drugs
References
27. Antifungal drugs
Allylamines [SEDA-31, 457; SEDA-32, 491; SEDA-33, 541]
Amphotericin [SED-15, 192; SEDA-31, 458; SEDA-32, 493; SEDA-33, 542]
Antifungal azoles [SED-15, 301; SEDA-31, 459; SEDA-32, 497; SEDA-33, 545]
Echinocandins [SED-15, 1197; SEDA-31, 464; SEDA-32, 507; SEDA-33, 556]
Flucytosine [SED-15, 1388; SEDA-32, 497; SEDA-33, 000]
References
28. Antiprotozoal drugs
Antimalarial drugs
4-Aminoquinolines (chloroquine and congeners) [SEDA-31, 469; SEDA-32, 521; SEDA-33, 567]
Primaquine and congeners [SED-15, 2919; SEDA-33, 569]
Endoperoxides [SED-15, 342; SEDA-31, 473; SEDA-32, 525; SEDA-33, 571]
Drugs used in the treatment of other protozoal infections
Miscellaneous drugs
References
29. Antiviral drugs
Drugs active against cytomegalovirus
Drugs active against herpesviruses [SEDA-31, 478; SEDA-32, 530; SEDA-33, 577]
Drugs active against hepatitis viruses
Drugs active against human immunodeficiency virus: Combinations
Drugs active against human immunodeficiency virus: Nucleoside analogue reverse transcriptase inhibitors (NRTI) [SED-15, 2586; SEDA-31, 482; SEDA-32, 534; SEDA-33, 585]
Drugs active against human immunodeficiency virus: Nucleotide analogue reverse transcriptase inhibitors
Drugs active against human immunodeficiency virus: Non-nucleoside reverse transcriptase inhibitors (NNRTI) [SED-15, 2553; SEDA-31, 486; SEDA-32, 537; SEDA-33, 590]
Drugs active against human immunodeficiency virus: Protease inhibitors [SED-15, 2586; SEDA-31, 487; SEDA-32, 541; SEDA-33, 593]
Drugs active against human immunodeficiency virus: Inhibitors of HIV fusion [SEDA-28, 337; SEDA-33; 598; SEDA-33, 598]
Drugs active against human immunodeficiency virus: Integrase inhibitors [SEDA-33, 599]
Drugs active against human immunodeficiency virus: Chemokine receptor CCR5 antagonists [SEDA-33, 600]
Drugs active against influenza viruses: Neuraminidase inhibitors [SED-15, 2436; SEDA-31, 489; SEDA-32, 544; SEDA-33, 601]
Drugs active against influenza viruses: Ion channel inhibitors [SED-15, 105, 3051; SEDA-31, 489; SEDA-32, 544; SEDA-33, 269, 602]
References
30. Drugs used in tuberculosis and leprosy
Rifamycins [SED-15, 3040; SEDA-31, 498; SEDA-32, 563; SEDA-33, 637]
References
31. Antihelminthic drugs
Benzimidazoles [SED-15, 424; SEDA-31, 508; SEDA-32, 572; SEDA-33, 647]
References
32. Vaccines
General
Bacterial vaccines
Viral vaccines
Other components of vaccines
References
33. Blood, blood components, plasma, and plasma products
Albumin and derivatives [SED-15, 54; SEDA-31, 527; SEDA-32, 591; SEDA-33, 670]
Blood transfusion [SED-15, 529; SEDA-31, 528; SEDA-32, 593; SEDA-33, 671]
Blood substitutes [SEDA-31, 531; SEDA-32, 593; SEDA-33, 672]
Plasma and plasma products [SED-15, 2847; SEDA-31, 532; SEDA-32, 594; SEDA-33, 674]
Plasma substitutes [SEDA-31, 533; SEDA-32, 594; SEDA-33, 675]
Globulins
Coagulation proteins [SED-15, 845; SEDA-31, 537; SEDA-32, 596; SEDA-33, 679]
Erythropoietin and derivatives [SED-15, 1243; SEDA-31, 538; SEDA-32, 597; SEDA-33, 681]
Stem cells [SEDA-31, 539; SEDA-32, 599; SEDA-33, 682]
References
34. Vitamins, intravenous solutions, and drugs and formulations used in nutrition
Vitamin A (carotenoids) [SED-15, 3642; SEDA-31, 548; SEDA-32, 607; SEDA-33, 691]
Vitamins of the B group [SED-15, 2700; SEDA-31, 548; SEDA-32, 608; SEDA-33, 693]
Vitamin C (ascorbic acid) [SED-15, 351; SEDA-31, 548; SEDA-32, 611; SEDA-33, 694]
Vitamin D analogues [SED-15, 3669; SEDA-31, 549; SEDA-32, 612; SEDA-33, 695]
Vitamin E (tocopherol) [SED-15, 3677; SEDA-31, 549; SEDA-32, 612; SEDA-33, 696]
Vitamin K analogues [SED-15, 3681; SEDA-29, 355]
Parenteral nutrition [SED-15, 2700; SEDA-31, 549; SEDA-32, 613; SEDA-33, 697]
Enteral nutrition [SED-15, 1221; SEDA-30, 396; SEDA-33, 700]
References
35. Drugs that affect blood coagulation, fibrinolysis, and hemostasis
Coumarin anticoagulants [SED-15, 983; SEDA-31, 553; SEDA-32, 617; SEDA-33, 707]
Heparins [SED-15, 1590; SEDA-31, 556; SEDA-32, 626; SEDA-33, 713]
Direct thrombin inhibitors [SED-15, 1142; SEDA-30, 409; SEDA-31, 559; SEDA-32, 632; SEDA-33, 717]
Direct factor Xa inhibitors [SEDA-31, 561; SEDA-32, 635]
Indirect factor Xa Inhibitors [SEDA-31, 563; SEDA-32, 636; SEDA-33, 636]
Thrombolytic drugs
Drugs that alter platelet function [SEDA-30, 413; SEDA-31, 564; SEDA-32, 637; SEDA-33, 637]
Glycoprotein IIb–IIIa inhibitors [SED-15, 4; SEDA-31, 565; SEDA-32, 638; SEDA-33, 720]
Thienopyridines [SED-15, 821; SEDA-31, 566; SEDA-32, 639; SEDA-33, 720]
Hemostatic agents
References
36. Gastrointestinal drugs
Antacids [SED-15, 243; SEDA-31, 573; SEDA-32, 665; SEDA-33, 741]
Antiemetics and drugs that affect gastrointestinal motility [SEDA-31, 573; SEDA-32, 665; SEDA-33, 741]
5HT3 receptor antagonists [SED-15, 1365; SEDA-31, 575; SEDA-32, 666; SEDA-33, 744]
Neurokinin NK1 receptor antagonists [SEDA-32, 667; SEDA-33, 748]
Histamine H2 receptor antagonists [SED-15, 1629; SEDA-31, 576; SEDA-32, 667; SEDA-33, 748]
Proton pump inhibitors [SED-15, 2973; SEDA-31, 577; SEDA-32, 667; SEDA-33, 749]
Other ulcer-healing agents
Laxatives and oral bowel preparations [SED-15, 2008; SEDA-31, 581; SEDA-32, 668; SEDA-33, 753]
Aminosalicylates [SED-15, 138; SEDA-31, 583; SEDA-32, 669; SEDA-33, 756]
Antidiarrheal agents
Other gastrointestinal agents
References
37. Drugs that act on the immune system: cytokines and monoclonal antibodies
Colony-stimulating factors [SEDA-31, 589; SEDA-32, 675; SEDA-33, 769]
Interferons [SED-15, 1841; SEDA-31, 591; SEDA-32, 676; SEDA-33, 773]
Interleukins [SED-15, 1831; SEDA-31, 592; SEDA-32, 676; SEDA-33, 777]
Tumor necrosis factor alfa (TNF-α) and its antagonists [SEDA-31, 592; SEDA-32, 677; SEDA-33, 779]
Monoclonal antibodies [SED-15, 2380; SEDA-31, 602; SEDA-32, 686; SEDA-33, 783]
References
38. Drugs that act on the immune system
Thiopurines [SED-15, 377; SEDA-31, 635; SEDA-32, 717; SEDA-33, 824]
Immunoenhancing drugs
References
39. Corticotrophins, corticosteroids, and prostaglandins
Systemic glucocorticoids [SED-15, 906; SEDA-31, 651; SEDA-32, 723; SEDA-33, 841]
Prostaglandins and analogues [SED-15, 2955; SEDA-31, 651; SEDA-32, 729; SEDA-33, 846]
References
40. Sex hormones and related compounds, including hormonal contraceptives
Estrogens [SED-15, 1253; SEDA-31, 657; SEDA-32, 736; SEDA-33, 852]
Hormonal contraceptives [SED-15, 1642; SEDA-31, 663; SEDA-32, 741; SEDA-33, 858]
Antiestrogens and selective estrogen receptor modulators (SERMs) [SEDA-31, 664; SEDA-32, 743; SEDA-33, 859]
Progestogens [SED-15, 2930; SEDA-31, 669; SEDA-32, 747; SEDA-33, 865]
Prostaglandins (See alsoChapters 39 and 47)
Progesterone antagonists [SEDA-31, 671; SEDA-32, 749; SEDA-33, 866]
Sex hormone antagonists
Anabolic steroids, androgens, and related compounds [SED-15, 216; SEDA-31, 672; SEDA-32, 751; SEDA-33, 868]
Antiandrogens [SEDA-31, 673; SEDA-32, 755; SEDA-33, 872]
References
41. Thyroid hormones, iodine, and antithyroid drugs
Thyroid hormones [SED-15, 3409; SEDA-31, 687; SEDA-32, 763; SEDA-33, 881]
Iodine and iodides [SED-15, 1896; SEDA-31, 688; SEDA-32, 764; SEDA-33, 883]
Antithyroid drugs [SED-15, 3387; SEDA-31, 689; SEDA-32, 765; SEDA-33, 884]
References
42. Insulin, other hypoglycemic drugs, and glucagon
Insulin [SED-15, 1761; SEDA-31, 689; SEDA-32, 769; SEDA-33, 889]
Amylin analogues [SEDA-31, 692; SEDA-32, 773; SEDA-33, 893]
Biguanides [SED-15, 506; SEDA-31, 692; SEDA-32, 773; SEDA-33, 893]
Dipeptidyl peptidase 4 (DDP-4) inhibitors [SEDA-31, 693; SEDA-32, 774; SEDA-33, 894]
Incretin mimetics [SEDA-31, 695; SEDA-32, 775; SEDA-33, 896]
Meglitinides [SED-15, 2238; SEDA-31, 695; SEDA-32, 776; SEDA-33, 897]
Sodium–glucose transporter type 2 (SGLT2) inhibitors [SEDA-33, 898]
Sulfonylureas [SED-15, 3230; SEDA-31, 695; SEDA-32, 777; SEDA-33, 898]
Thiazolidinediones (Glitazones) [SED-15, 3380; SEDA-31, 697; SEDA-32, 779; SEDA-33, 899]
Peroxisome proliferator-activated dual receptor agonists [SEDA-32, 782; SEDA-33, 902]
References
43. Miscellaneous hormones
Vasopressin receptor antagonists
Vasopressin and analogues [SED-15, 3609; SEDA-31, 710; SEDA-32, 798; SEDA-33, 915]
References
44. Drugs that affect lipid metabolism
Cholesteryl ester transfer proteins [SEDA-32, 817; SEDA-33, 929]
Fibrates [SED-15, 1358; SEDA-32, 804; SEDA-33, 922]
HMG-CoA REDUCTASE INHIBITORS [SED-15, 1632; SEDA-31, 715; SEDA-32, 807; SEDA-33, 924]
Nicotinic acid derivatives [SED-15, 2512; SEDA-32, 815; SEDA-33, 928]
References
45. Cytostatic and cytotoxic drugs
Pyrimidine analogues and fluoropyrimidines
Pyrimidine analogues
Fluoropyrimidines
References
46. Radiological contrast agents and radiopharmaceuticals
MRI contrast media
Ultrasound contrast agents [SED-15, 3543; SEDA-32, 855; SEDA-33, 971]
Radiopharmaceuticals [SED-15, 3017; SEDA-33, 973]
References
47. Drugs used in ocular treatment
Drugs used in the management of macular degeneration [SEDA-31, 739; SEDA-32, 865; SEDA-33, 977]
Adrenoceptor agonists [SEDA-31, 740; SEDA-32, 869; SEDA-33, 982]
Alpha-adrenoceptor agonists
Antibacterial drugs
Anticholinergic drugs
Carbonic anhydrase inhibitors
Glucocorticosteroids [SED-15, 906; SEDA-31, 741; SEDA-32, 871; SEDA-33, 983]
Non-steroidal anti-inflammatory drugs
Prostaglandin analogues (See also Chapter 39)[SEDA-32, 871; SEDA-33, 984]
Procedures
References
48. Treatments used in complementary and alternative medicine
Asian herbal medicines [SED-15, 1609; SEDA-32, 879]
Oral formulations of traditional Chinese medicines
Topical formulations of traditional Chinese medicines
Injectable formulations of Chinese medicines
Nutritional supplements
Specific plants
Acupuncture
Infrared heat and massage therapy
References
49. Miscellaneous drugs, materials, medical devices, and techniques
DyestuffS
Sclerosants [SED-15, 3107; SEDA-33, 1021]
References
Index of drugs
Index of drug-drug interactions
Index of adverse effects and adverse reactions
- No. of pages: 904
- Language: English
- Edition: 1
- Volume: 34
- Published: December 14, 2012
- Imprint: Elsevier
- Hardback ISBN: 9780444594990
- eBook ISBN: 9780444595034
JA
Jeffrey K Aronson
Affiliations and expertise
Reader in Clinical PharmacologyRead Side Effects of Drugs Annual on ScienceDirect